University of Leicester
Browse
R3_clean final version.docx (45.28 kB)

Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes

Download (45.28 kB)
journal contribution
posted on 2021-01-15, 08:48 authored by Francesco Zaccardi, David E Kloecker, John B Buse, Chantal Mathieu, Kamlesh Khunti, Melanie J Davies
Over the last two decades, the large majority of clinical guidelines on the treatment of hyperglycaemia in subjects with type 2 diabetes have suggested metformin as the first-line glucose-lowering treatment alongside lifestyle changes to reach personalized glycemictargets. Recently, the European Society of Cardiology (ESC) recommended using glucagon-like peptide 1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter 2 inhibitors(SGLT-2is) as first line glucose-lowering therapy in subjects with type 2 diabetes at high or very high risk of cardiovascular disease (CVD), ahead of metformin treatment, to reduce cardiovascular events.

History

Citation

Diabetes Care 2020 Dec; dc202080. https://doi.org/10.2337/dc20-2080

Author affiliation

Diabetes Research Centre, College of Life Sciences

Version

  • AM (Accepted Manuscript)

Published in

Diabetes Care

Pagination

dc202080

Publisher

American Diabetes Association

issn

0149-5992

eissn

1935-5548

Copyright date

2020

Available date

2020-12-17

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC